PER-037-14Completed未知
PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- PFIZER S.A.,
- Enrollment
- 190
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 50 to 99 (—)
Inclusion Criteria
- •1.Moderate to severe rheumatoid arthritis
- •2.Taking methotrexate without adequate control of symptoms
- •3.Have at least one cardiovascular risk factor (eg, current smoker, high blood pressure, high cholesterol levels, diabetes mellitus, history of heart attack, family history of coronary heart disease, extra-articular RA disease)
Exclusion Criteria
- •1.Current or recent infection
- •2.Clinically significant laboratory abnormalities
- •3.Pregnancy
Investigators
Similar Trials
Active, not recruiting
Phase 1
A clinical study to evaluate the safety of two different doses of Tofacitinib for the treatment of rheumatoid arthritis.MedDRA version: 19.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2013-003177-99-SEPfizer Inc. 235 East 42nd Street, New York, 100174,000
Active, not recruiting
Phase 1
A clinical study to evaluate the safety of two different doses of Tofacitinib for the treatment of rheumatoid arthritis.MedDRA version: 19.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2013-003177-99-ATPfizer Inc. 235 East 42nd Street, New York, 100174,000
Active, not recruiting
Phase 1
A clinical study to evaluate the safety of two different doses of Tofacitinib for the treatment of rheumatoid arthritis.MedDRA version: 21.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2013-003177-99-FIPfizer Inc., 235 East 42nd Street, New York, 100174,000
Active, not recruiting
Phase 1
A clinical study to evaluate the safety of two different doses of Tofacitinib for the treatment of rheumatoid arthritis.MedDRA version: 20.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2013-003177-99-CZPfizer Inc.4,000
Active, not recruiting
Phase 1
A clinical study to evaluate the safety of two different doses of Tofacitinib for the treatment of rheumatoid arthritis.MedDRA version: 20.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2013-003177-99-SKPfizer Inc.4,000